Translating dosages from animal models to human clinical trials—revisiting body surface area scaling
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Body surface area (BSA) scaling has been used for prescribing individualized dosages of various drugs and has also been recommended by the U.S. Food and Drug Administration as one method for using data from animal model species to establish safe starting dosages for first‐in‐human clinical trials. Although BSA conversion equations have been used in certain clinical applications for decades, recent recommendations to use BSA to derive interspecies equivalents for therapeutic dosages of drug and natural products are inappropriate. A thorough review of the literature reveals that BSA conversions are based on antiquated science and have little justification in current translational medicine compared to more advanced allometric and physiologically based pharmacokinetic modeling. Misunderstood and misinterpreted use of BSA conversions may have disastrous consequences, including underdosing leading to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse events. We aim to demonstrate that recent recommendations for BSA are not appropriate for animal‐to‐human dosage conversions and use pharmacokinetic data from resveratrol studies to demonstrate how confusion between the “human equivalent dose” and “pharmacologically active dose” can lead to inappropriate dose recommendations. To optimize drug development, future recommendations for interspecies scaling must be scientifically justified using physiologic, pharmacokinetic, and toxicology data rather than simple BSA conversion.—Blanchard, O. L., Smoliga, J. M. Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. FASEB J. 29, 1629‐1634 (2015). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerning dosing, differences in metabolism, weight, distribution volume etc. result in different dosing, and oversimplified approaches for dose prediction are common [87].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [87]
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 10×
“62 mg/kg, or;98 mg for a 60 kg human(3, 55).”
BackgroundMethodInfluentialResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290 · cited 3×
“(51), or any animal model study, into a human equivalent dosage for therapeutic effect.”
BackgroundLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 2×
“Reagan-Shaw’s example for the “inappropriate comparisons between studies” for pharmacologic effect in humans stemmed from the discussion of resveratrol dosage in the literatureandpress (3, 51, 52).”
BackgroundKleiber, M. (1932) · Hilgardia · doi:10.3733/hilg.v06n11p315 · Cited by 2,222 · cited 1×
“The statements by Pinkel that blood volume, circulating plasma proteins, and renal function correlated with a surface law had already been disproven in the literature for over a decade when published in 1958, and there is no reason to perpetuate misinformation by allowing it to stay in themodern literature without pro…”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Clinical Methods: The History, Physical, and Laboratory Examinations
Kruse, J. A. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210108045 · Cited by 2,029
Quantitative Laws in Metabolism and Growth
von Bertalanffy, L. (1957) · The Quarterly Review of Biology · doi:10.1086/401873 · Cited by 2,029 · cited 4×
“The use of allometry for pharmacokinetic prediction originates from work in metabolic scaling, which plotted the formula to fit the metabolic rate and body weight of animals on double logarithmic scale (10, 29, 41).”
BackgroundMethodInfluentialHIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., & Walle, U. K. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000885 · Cited by 1,880
Kleiber, M. (1947) · Physiological Reviews · doi:10.1152/physrev.1947.27.4.511 · Cited by 1,817 · cited 8×
“In 1947, Kleiber (11) made a reductio ad absurdum argument to discredit the claims of Dreyer and Ray (18, 19), which is equally applicable to Pinkel (17) from 1958 and Reagan-Shaw et al. (3) from 2008.”
BackgroundMethodInfluentialLost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
Research works printed but not linked: 4
- Center for Drug Evaluation and Research, 2002, Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, Draft Guidance
- Rubner M., 1883, Über den einfluss der körpergrösse auf stoff- und kraftwechsel, Zeit. Biol., 19, 536
- Center for Drug Evaluation and Research, 2005, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
- Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling
Cited by
Items 101–183 of 183
Sodium dithionate (Na2S2O4) induces oxidative damage in mice mitochondria heart tissue
gashti, R. Z., & Mohammadi, H. (2022) · Toxicology Reports · doi:10.1016/j.toxrep.2022.06.016 · Cited by 11
Joung, J., Lee, J., Cho, J.-H., Lee, D., & Son, C. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2588-3 · Cited by 8
Choi, S., Kim, C., Son, H., Hwang, J., & Kang, W. (2020) · Journal of Medicinal Food · doi:10.1089/jmf.2019.4564 · Cited by 14
“17 They insisted that interspecies scaling can be justified using pharmacokinetic data rather than simple conversion with body surface area.”
Han, M., Lian, J., Su, Y., & Deng, C. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050549 · Cited by 8
“However, the dosage translation method based on body surface area has been strongly criticized, since it is not accurate for determining therapeutic dosage conversions (Blanchard and Smoliga, 2015).”
MethodSu, H., Xue, H., Gao, S., Yan, B., Wang, R., Tan, G., Xu, Z., & Zeng, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.930912 · Cited by 8
“Following the animal dose conversion formula (19), Rhizoma Drynariae gavage was administered at a potency of 8.”
MethodJebari, K., Charradi, K., Mahmoudi, M., Kadri, S., Ben‐Attia, M., Mousslim, M., May, M. V. E., Limam, F., & Aouani, E. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab259 · Cited by 8
Kundrick, E. R., Marrero-Rosado, B. M., Furtado, M. D. A., Stone, M. F., Schultz, C. R., & Lumley, L. A. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.12.002 · Cited by 7
Hamad, R. S., Hasan, W. A., Elmorsy, E. A., Farrag, A. A. M., Abdelaziz, M. A., Alalawy, A. I., Alsirhani, A. M., Dawsari, M. M. A., El-kott, A. F., AlShehri, M. A., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178202 · Cited by 5
Basirinia, G., Comelli, A., Alongi, P., Ali, M. U., Salvaggio, G., Longo, C., Raimondo, D. D., Tuttolomondo, A., & Benfante, V. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010036 · Cited by 7
“…an appropriate starting dose is important to ensure patient safety, to enable efficiency in reaching the therapeutically relevant dose range [132], and to use data from animal model species and human equivalent models to establish safe starting dosages for first-in-human clinical trials [133].”
Bılgın, B., Adam, M., Hekım, M. G., Bulut, F., & Özcan, M. (2024) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2024.04.007 · Cited by 6
Xu, X., Wang, X., Zhang, L., Jin, Y., Li, L., Jin, M., Li, L., & Ni, H. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01490 · Cited by 7
Gajardo, A. I. J., Lillo‐Moya, J., San‐Martín‐Martinez, D., Pozo-Martínez, J., Morales, P. E., Prieto, J. C., Aguayo, R., Puentes, Á., Ramos, C., Silva, S., et al. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1443 · Cited by 6
“However, since target drug concentrations can vary between rat studies and humans, 26,27 further studies are needed to confirm the therapeutic concentrations in patients with AMI.”
Zhang, H., Zhang, Y., Zhang, Y., Wei, H., Jin, S., Huo, T., & Qin, L. (2025) · Food & Function · doi:10.1039/d4fo03096f · Cited by 6
Sun, X., He, L., Bi, H., Huang, M., Xiang, E., Li, X., Wang, H., & Guo, Y. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.03.002 · Cited by 7
Yang, S., Yang, J., Gong, X., Weiss, M. A., & Strano, M. S. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300587 · Cited by 8
Vejmola, Č., Šíchová, K., Syrová, K., Janečková, L., Koudelka, V., Tesař, M., Nikolič, M., Viktorinová, M., Tylš, F., Korčák, J., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100524 · Cited by 8
From bench to bedside: therapeutic potential of natural antioxidants in diabetic neuropathy
Zhang, Y., Yao, L., Lyu, Y., Tang, Z., Liu, X., & Duan, X. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1631678 · Cited by 8
“These inherent pharmacokinetic and pathophysiological gaps demand careful human-equivalent dosing and long-term translational studies before antioxidant benefits can be claimed (Reagan-Shaw et al., 2008; Sharma and McNeill, 2009; Blanchard and Smoliga, 2015).”
Zhang, Z., Xiao, S., Tian, D., Lin, T., Luo, K., Peng, D., Bo, Y., Guo, A., Hu, Y., Wu, L., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115723 · Cited by 5
Tetramethylpyrazine: A fermented alcohol product that mitigates alcoholic liver disease in mice
Pu, Q., Gao, H., Xiao, D., Wang, M., Yang, Z., He, Q., Liu, M., Zhu, X., Pan, T., Ma, Z., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.05.415 · Cited by 6
Primaquine-chitosan Nanoparticle Improves Drug Delivery to Liver Tissue in Rats
Louisa, M., Hawa, P., Purwantyastuti, P., Mardliyati, E., & Freisleben, H. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.10005 · Cited by 5
“Primaquine dose selected was based on the equivalence to human dose and calculated based on dose translation using body surface area [11], [12], [13].”
MethodPopović, D. J., Popović, K. J., Miljković, D., Popović, J. K., Lalošević, D., Poša, M., Dolicanin, Z. C., & Čapo, I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115528 · Cited by 4
RetractedSu, H., Yan, B., Wang, R., Li, Z., Xu, Z., Xue, H., & Tan, G. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073261905231110061401 · Cited by 5
“After successfully molded, the OVXDF group will refer to the animal dose conversion formula [15], and the Drynaria rhizome decoction was administered (intragastric administration) at the gavage dose was 0.48g/kg..”
MethodHuang, L., Zou, J., Zhang, Y., Gu, J., Wu, J., & Zhang, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-075138 · Cited by 4
“While physiological, pharmacokinetic and toxicology data are recommended for interspecies scaling rather than simple BSA conversion to optimise drug development, 36 the pharmacokinetic processes of stem cells in the human body, especially in children, remain unclear.”
Feng, Z., Geng, Z.-J., Qin, S., Hu, H., Tan, X.-Y., Zeng, S.-Y., Zhou, R.-Y., Ma, X., Liu, Y., & Zhang, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156639 · Cited by 4
Early, very high-dose, and prolonged vitamin C administration in murine sepsis
Kim, O., Kim, T. W., Kang, H., Jeon, T. J., Chang, E. S., Lee, H. J., & Kim, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-02622-7 · Cited by 5
“Translating the duration and dosage of vitamin C treatment obtained from animal models to human patients is difficult because the rates of metabolic and inflammatory responses vary across species 39 .”
Creecy, A., Smith, C., & Wallace, J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-14068-2 · Cited by 4
Sun, X., Liu, J., Xiang, E., Li, X., Yan, X., Wang, D., Li, F., Kou, H., Wang, H., & Guo, Y. (2025) · Advanced Science · doi:10.1002/advs.202515583 · Cited by 4
Shu, G., Xiao, L., Lei, Y., Zhang, T., Sun, H. M., Wang, C., Song, A., & Deng, X. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105634 · Cited by 3
Khandelwal, V. K. M., Singh, P., Ravíngerová, T., & Chaudhary, M. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 3
Pharmacokinetics of low‐dose methotrexate in horses
Rostang, A., Desjardins, I., España, B., Panzuti, P., Berny, P. J., Prouillac, C., & Pin, D. (2020) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12857 · Cited by 3
Melatonin as a Chronobiotic and Cytoprotector in Healthy Aging
Cardinali, D. P., Pandi-Perumal, S. R., & Brown, G. M. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-22468-3_14 · Cited by 3
The Key Concepts of Animal Models
Sreelatha, H. V., Patel, S., & Nagarajan, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-0048-6_1 · Cited by 3
Zhu, M.-H., Wen, Q., Lin, T., Gao, Y., Liu, X., Lin, J.-H., Lin, M., & Shi, Q.-M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1590362 · Cited by 2
Ribeiro, K. R., Silva, R. B. E., Rodrigues, J. P. C., Coimbra, M. C., Pereira, L. J., Alves, E. D. O., de Oliveira, F. M., Pereira, M. O. A., Gil, E. D. S., Carollo, C. A., et al. (2025) · Plants · doi:10.3390/plants14132008 · Cited by 2
“To bridge this gap, various dose conversion strategies between animals and humans could help estimate a safe starting dose, ensuring safety and tolerability in phase I clinical trials [53,54].”
Preclinical Assessment of a Metformin–Melatonin Combination: Antinociceptive Synergism
Gauthereau‐Torres, M. Y., Martínez-Guillen, J. S., Cervantes‐Durán, C., Gutiérrez-García, C. J., Godínez‐Hernández, D., Méndez, A. A., & Ortega‐Varela, L. F. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081057 · Cited by 2
“Other validated approaches with physiologic and pharmacokinetic data will be needed to determine the therapeutic ranges of a metformin–melatonin combination in humans [82].”
Wang, Q., Yang, F., Wang, X., Ma, X., Yang, X., Li, L., Cao, S., & Wa̅ng, Y. (2025) · Environment & Health · doi:10.1021/envhealth.5c00167 · Cited by 3
“43 A high dose of 200 mg/kg · bw/d was selected based on previous studies on DEHP neurotoxicity.”
Raslan, H. A., Michel, H. E., Menze, E. T., & El-Gazar, A. A. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10271-w · Cited by 2
“Thus, body surface area (BSA)-based HED conversions fail to account for critical physiological and pharmacokinetic differences between species (Blanchard and Smoliga 2015).”
Cell‐based allometry: an approach for evaluation of complexity in morphogenesis
Tarihi, A., Tarihi, M., & Tiraihi, T. (2023) · Quantitative Biology · doi:10.15302/j-qb-022-0319 · Cited by 2
Cho, N., Ho, J., Rosario, G. D., Yu, S., Ferl, G. Z., & Boswell, C. A. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01207-9 · Cited by 4
Mycosubtilin Induces G1 Phase Block and Autophagy in Cervical Cancer HeLa Cells
Li, H., Zhou, D., Wang, W., Aimaier, R., JunYang, J., Zhao, H., Zhao, H., Li, J., Pang, X., Zhou, Q., et al. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10534-1 · Cited by 3
Sharma, A., Thakur, A., Chorawala, M. R., Rawal, R., & Shrivastava, N. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106973 · Cited by 3
Lança, M. L. D. A., da CONCEIÇÃO, N. S. C., Malta, I. S., Meneses, D. O., Almeida, L. Y., & Kaminagakura, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178120 · Cited by 4
“ART (Sigma-Aldrich, St. Louis, MO, USA) was diluted in 1.6 mL of Dimethyl Sulfoxide (DMSO) (Neon Surface, SK, Canada) and administered via intraperitoneal injection at a dose of 85 mg/kg per week [44–46].”
InfluentialZueva, I. V., Lenina, O. A., Kayumova, R. M., Petrov, K. A., & Masson, P. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109558 · Cited by 2
Zheng, Y., Chen, Z., Sun, X., Wang, F., Tang, X., Li, L., Wang, Y., & Zhang, L. (2025) · Blood Purification · doi:10.1159/000545291 · Cited by 1
“BSA scaling has been utilized to prescribe individualized dosages for various drugs [47], and when compared with fi xed doses, BSA-based dosing demonstrated signi fi cantly greater precision [48].”
Zhao, L., Jiang, Y., Ma, J., Yang, Y., Liu, G., Wang, Z., Wong, T. W., & Zhang, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1667685 · Cited by 2
Li, Q.-M., Hu, D., Yin, K., Wu, P., Hu, J., Chen, X.-M., Shan-shan, W., Li, X.-L., Cai, X.-Y., Hou, F.-Y., et al. (2026) · Environment International · doi:10.1016/j.envint.2026.110162 · Cited by 1
Popović, K. J., Popović, D. J., Miljković, D., Popović, J. K., Poša, M., Drljača, J., & Dolićanin, Z. (2026) · Pharmaceuticals · doi:10.3390/ph19030407 · Cited by 1
Jin, T., Xu, R., Jiang, Z., Ma, J., & Li, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1800063 · Cited by 1
Deng, Q., Yao, Z., Song, A., Lei, X., Jiang, S., Song, Y., Zheng, Z., Zheng, S., Yu, H., Chen, L., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118334 · Cited by 1
Improving Animal Diets to Increase Relevance to Human Populations
Hintze, K. J., Benninghoff, A. D., & Ward, R. E. (2017) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v7i5.340 · Cited by 1
Mouse Models to Study Antiobesogenic Effects of Carotenoids
Ribot, J., Stojnic, B., Palou, A., & Bonet, M. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9952-1_30 · Cited by 1
Bilal, M., Ullah, S., Jaehde, U., Trueck, C., Zaremba, D., Wachall, B., Wargenau, M., Scheidel, B., Wiesen, M. H. J., Gazzaz, M., et al. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03697-3 · Cited by 1
“The U.S. Food and Drug Administration recommends BSA scaling for using animal model species data to establish safe starting doses for the first in human clinical studies [58].”
MethodLi, Z., Long, Y., Sun, X., Liu, A., Ding, Z., Li, D., Wang, Y., Zeng, R., Liu, Q., Chen, B., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157016 · Cited by 3
Challenges of Obtaining Evidence-Based Information Regarding Medications and Male Fertility
Drobnis, E. Z., & Nangia, A. K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-69535-8_2 · Cited by 1
“Pharmacokinetic data would be the most appropriate method for determining HED (Blanchard and Smoliga 2015); however, the data required are not readily available.”
MethodInfluentialModulation of inflammatory responses by Sutherlandia frutescens
Lei, W. (2015) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/50153 · Cited by 2
Tools to enable animal to human translation: Assessing the value of disease models
Ferreira, G. S. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/157 · Cited by 2
Chapter 11 Zyfl amend and Prostate Cancer Therapy
Whelan, J. N., Zhao, Y., Huang, E., MacDonald, A., & Donohoe, D. R. (2016) · Traditional herbal medicines for modern times · doi:10.1201/9781315370156-12 · Cited by 1
Crovetto, G. M. A. (2017) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/25293
Litvak, Y. V., Harapko, Т. V., Lytvak, V. V., & Foros, A. I. (2022) · Wiadomości Lekarskie · doi:10.36740/wlek202212135
Reynolds, P. S. (2023) · Wiley eBooks · doi:10.1002/9781119800002.ch22
Empirical and Translational Pilots
Reynolds, P. S. (2023) · Wiley eBooks · doi:10.1002/9781119800002.ch6
Liu, Y., Xiao, H., Li, B., Wang, H., & Chen, L. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250218 · Cited by 1
Hamlaoui, S., Smadhi, H., Aouani, E., & Mezghani, S. (2025) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-025-03319-x
Khromov, A., Dobrelia, N. V., Konvalyuk, I. I., Bieda, O. A., Andreev, I. O., Mozhylevska, L. P., Yarmoluk, S. M., Soloviev, A. I., & Kunakh, V. A. (2025) · Planta Medica · doi:10.1055/a-2629-0226
He, K., He, L., Wei, X., Wang, X., Zhou, M., Cao, Y., Luo, X., & He, J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149929
Xia, S., Wu, J., Duan, J., Ye, W., Sun, Y., Yang, X., Chen, X., Lin, H., Huang, S., Cai, J., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117094
“To ensure translational relevance, we employed a dose-dependent administration strategy (10–100 mg/kg) based on human equivalent dose (HED) conversion using the U.S. Food and Drug Administration (FDA)-recommended body surface area (BSA) normalization method 32 (conversion factor ≈ 3).”
Chen, W. L., Ge, M., Sun, S., Zhang, H., Wang, Z., Guo, Y., & Luo, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-32406-y · Cited by 1
Sun, X., Li, S., Zhao, L., Wang, X., Wei, X., & Sun, G. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.116829 · Cited by 1
Jung, S. M., Ha, A. W., & Kim, W. (2026) · Nutrition Research and Practice · doi:10.4162/nrp.2026.20.1.46
“…when the doses were converted using the human equivalent dose calculation method for a 70 kg adult, they corresponded to approximately 1 and 2 mg, respectively, which is a level that can be consumed routinely through raw garlic (0.1–2.3 mg/g) or garlic-derived foods such as black garlic [31].”
InfluentialStandardization of canine infections for the development of antileishmanial drugs
Olías-Molero, A. I., Corral, M. J., Jiménez-Antón, M. D., Mateo, M., Carrión, J., Torrado, J. J., & Alunda, J. M. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1754269
Nueraihemaiti, M., Kamoldinov, K., Lu, X., Niu, C., Tang, D., Zhao, J., & Aisa, H. A. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157949
Qiju Granule alleviates retinal damage in a mouse model of age-related macular degeneration
Chen, Q., Zhang, J., Xu, K., Liu, X., & Liang, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1781217
Cheng, Z., Xiang, W., Chen, X., Xu, X., Hou, W., Gao, J., & Zhou, J. (2026) · Fitoterapia · doi:10.1016/j.fitote.2026.107239
Kocsy, K., Wilkinson, H. S., Sokolowska, Z., Bolger, L. F., Kumar, V., An, Y., Felix-Ilemhenbhio, F., McNeill, A., Jain, S. R., Agtmael, T. V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723462
“It was delivered in the drinking water from mating until 3 months of age at 20 mg/kg/day (a safe dose in humans (33, 34).”
Jusuf, A. A., Fadilah, & Nirwanti, N. A. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102290
“Limitations include: (1) rat model limits human extrapolation [8,9]; Reagan-Shaw scaling does not account for species-specific pharmaco-kinetics [25,42]; (2) PND14 assessment misses long-term outcomes [7]; (3) n = 4 dams/group underpowered for biochemical markers (power 15 – 42%; n ≈ 64 needed for…”
Lei, Y.-N., Yu, Y., Duan, X.-Q., & Wang, J. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158486
Repurposing Evacetrapib as a membrane disruption agent inducing rapid autolysis in MRSA
Lei, D., Qiu, J., Fang, Z., Chen, J., He, Q., Ge, R., & Sun, X. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108663
Jurowski, K., & Noga, M. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112221
Ginkgo biloba extract as a retinal protective agent: a systematic review of preclinical experiments
Shi, N., Li, J., Yan, Y., Jin, Y., Zhang, W. L., Shang, M., Wu, X., Cui, Y., & Liang, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12251-6
“Commonly used body surface area scaling methods provide only a conservative starting point for safety and do not predict pharmacologically effec - tive doses in humans [ 67, 68 ].”
Hou, Y., Wang, H., Li, J., Li, C., Sun, Y., Wang, Y., Zou, D., & Zhou, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1868875 · Cited by 2
Cardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity
Maikenova, A., Urazbayeva, A., Myrzabay, Z., Askambayeva, N., Gulyayev, A., Digai, A., Tauekelova, A., Nurgozhina, A., Mukhanbetzhanova, Z., & Aljofan, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188095 · Cited by 1
“…reported, a later clinical study using 100 mg resveratrol showed a substantially lower Cmax in humans (21.4 ng/mL) than that reported in mice (592 ng/mL), noting the limitations of relying on BSA-based dose conversion without considering pharmacokinetic differences between the two species [126].”
InfluentialChen, R., Liu, C., Li, X., Li, S., 童志荣, Hu, M., Li, Z., Xu, C., Wang, Z., Liu, X., et al. (2026) · Food & Function · doi:10.1039/d6fo03888c
Li, M., Li, R., Deng, Z., Zhang, L., Lv, S., Shi, J., Ma, H., Guan, W., Zhang, H., Li, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1918967
Metadata
- Authors
- Blanchard, O. L., & Smoliga, J. M.
- Affiliations
- Wilmore Labs Limited Liability Company San Antonio Texas USA
- High Point University (US)
- Corresponding author
- Smoliga, James M.
- ORCID
- Smoliga, James M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-02-05
- Volume
- 29
- Issue
- 5
- Pages
- 1629-1634
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2032445654
- Cited by
- 183
- References
- 61
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 16 · 2023: 14 · 2022: 22 · 2021: 22 · 2020: 14 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 6
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- interspecies scaling, resveratrol, human equivalent dose, allometric scaling, physiologically based pharmacokinetic modeling, drug dosing, translational medicine, adverse drug reactions
- MeSH terms
- Animals, Body Surface Area, Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, Species Specificity, Therapeutic Equivalency, Tissue Distribution, Drugs, Investigational, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.